Immunicum hires Lise-Lotte Hallbäck as new CFO

Gothenburg, Sweden, 2015-07-13 08:30 CEST (GLOBE NEWSWIRE) — Immunicum AB (publ) strengthens its organization with the recruitment of Lise-Lotte Hallbäck as CFO.

Lise-Lotte Hallbäck will assume the position on October 1st and most recently served as Head of the Gothenburg office at Visma Services AB. She has extensive experience in leading positions in accounting and financial management of internationally operating companies and has also worked as an authorized accountant.

“We are very pleased to strengthen our organization with Lise-Lotte, whom I had the privilege to get to know during the time she spent at her former employer. She is thus well versed in our business”, says Jamal El-Mosleh, CEO of Immunicum.

Lise-Lotte Hallbäck will replace Per-Olof Gunnesson, the Company’s current CFO, in the management team. Per-Olof Gunnesson, formerly a member of the Board of the Company, will continue to be linked to Immunicum as a consultant, focusing primarily on contractual issues.

“I’m really looking forward to taking the role as Immunicum’s CFO. Immunicum is an exciting company with good prospects. With my background and expertise, I think there is a lot I can bring to the organization with regards to financial processes and other issues related to business development”, says Lise-Lotte Hallbäck.

Hallbäck has a Bachelor of Science in Business Administration and Economics from the School of Economics at Växjö University.


For further information, please contact:

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52


The Company’s Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31.


About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company’s most advanced project – INTUVAX® against renal cancer – has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.

Keep reading

Immunicum includes first patient in a phase II study in patients with metastatic kidney cancer